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osting by Eª 2010 King Saud University. All rights reserved.1. IntroductionRapid developments in new health care technology in the car-
diac ﬁeld have become almost daily events. The technological
development involves a wide range of applications of diagnos-
tic modalities such as cardiac MRI, PET, CT angio or genetic
screening for cardiac risk factors. It also covers countless ther-
apeutic interventions, e.g., new anti-platelets, new pulmonary
vasodilators, implantable cardioverter-deﬁbrillators (ICD)
drug-eluting stents, off pump coronary bypass, ventricular as-
sist devices and robotic surgery. The term ‘‘technology creep’’
describes a phenomenon in which a certain technology ﬁrst gets
approved for a high-risk population in which there’s a proven
beneﬁt and its use then expands to lower-risk groups, changing
the calculus of clinical and ﬁnancial risk and reward. The ICD
was ﬁrst used for people who had survived cardiac arrest and
are now ‘‘recommended’’ for primary prevention in patientshoo.com
ity. All rights reserved. Peer-
d University.
lsevierwith low ejection fraction (Epstein et al., 2008). The estimated
cost per QALY for each device ranges between $50,300 and
$70,200 (Health Technol Assess, 2006). Cardiac centers com-
pete to attract doctors and patients by buying advanced tools.
If Hospital A has a PET scanner and cardiacMRI andHospital
B does not have them, Hospital B loses in reputation and vol-
ume. This is regardless of the degree of need or priority of the
presence of these technologies in certain community.
Unfortunately, adopting these new technologies can put a
huge burden in the health systems costs. The annual medical
cost of a CVD in USA is exceeding $403.1 billion (Patel and
et al., 2005). This is true not only at the individual patient
management but also at the nationwide level decisions to
adopt such technology. Since available resources are limited,
delivering health services involves making decisions. Decisions
are required on what interventions should be offered, the way
the health system is organized, and how the interventions
should be provided in order to achieve an optimal health gain
with available resources, while, at the same time, respecting
people’s expectations.2. Health technology assessment (HTA) as a continuum of
evidence-based medicine (EBM)
The practice of EBM depends on the strength of evidence
(level of evidence) and strength of recommendation (grade of
Figure 1 EBM concepts.
Figure 2 Hierarchy for level of evidence (in intervention).
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yses which are analysis of evidence and analysis of outcome.
The HTA process can be considered as an extension of the
EBM process with the addition of two more types of analyses
which are value analysis (cost/effectiveness) and appropriate-
ness analysis (ethical–legal and societal). These dimensions
are shown in Fig. 4.
2.1. Stage of evidence analysis – quality of evidence
The newest isn’t always ‘‘the best,’’ and the latest isn’t always
the right answer. It is now clear that interventions once
thought to be beneﬁcial have, in the light of more careful eval-
uation, turned out to be at best of no beneﬁt or harmful and
counterproductive to the system. The famous hormonal
replacement therapy HRT ‘‘recommendation’’ was adopted
to reduce cardiac risk in postmenopausal females based on sev-
eral observational studies. Later after better research quality
by RCT in Women’s Health Initiative (2002), this recommen-
dation proved to be harmful. This illustrated the importance of
practicing ‘‘Evidence-Based Medicine or EBM,’’ which argues
that the information should be based on rigorous research to
the fullest extent possible (Guyatt and et al., 2008). Fig. 1
shows the major concepts of EBM and the concept of best
available evidence. This concept implies a ‘‘hierarchy’’ of evi-
dence. Since the evidence comes from research, it is important
to consider (Fig. 2):
1. The hierarchy of research designs.
2. The quality of the research execution.
Some research studies are considered to be better than oth-
ers. Evidence from good research is considered to be better
than evidence resulting from research of a lesser standard. This
was very clear in HRT trials. The ﬁrst is an evidence analysis––
a systematic evaluation of evidence for a technology and a
requirement of good evidence for such things as coverage,
placement on formularies, and afﬁrmative guidelines. This
stage corresponds to the evidence-based guidelines (EBGs)
part of EBM.
2.2. Stage of outcome analysis – grade of recommendation and
beneﬁt/risk ratio
In general the strength of recommendations is related to the
strength of evidence and it was accepted that strong evidenceon the effects of an intervention (positive or negative) allows
for strong recommendations for or against the use of it. Weak
evidence only supports weak recommendations. For several
years, many systems established to link between the strength
of the evidence and the grade of recommendation and typically
using letters (for instance A, B, C, etc.) to describe the strength
of a recommendation. Over the last two decades it has been
realized that a recommendation based on the two elements
of study design and validity frequently is inadequate. The
GRADE system suggests that study quality should go beyond
validity to include other factors that can increase or decrease
its overall quality. In addition to the presence of any type of
bias (that reduces the validity), GRADE considered other fac-
tors that if present should reduce the quality namely inconsis-
tency, impression, indirectness and small magnitude of effect.
On the other hand, GRADE considered the presence of cer-
tain factors (beyond validity) should increase the overall qual-
ity (namely; presence of dose–response, strong association or
all plausible confounders would result in an underestimate of
the treatment effect). The major addition of the GRADE sys-
tem is in its methodology in moving from evidence to recom-
mendation. Since interventions may have both positive and
negative effects at the same time, GRADE system proposed
a framework to make explicit the trade-offs between harms
and beneﬁts (GRADE Working Group, 2004). Fig. 3 shows
a diagram explaining the GRADE system. The second stage
of outcomes analysis is an estimation of the magnitude of
the effects of the technology on the desired clinical outcomes
(the ‘‘beneﬁts’’) and on potential harms such as side effects
and risks (the ‘‘risks’’). This stage also includes a comparison
of beneﬁts and risks, to determine if the ‘‘beneﬁt–risk ratio’’
is sufﬁciently high to justify the technology.
2.3. Stage of value analysis
Here the researcher estimates the effect of the technology on
costs and compares the clinical effects against the costs to
determine if the ratio is sufﬁciently high. In this stage there will
be cost analysis and cost-effectiveness analysis. If this is com-
bined with the previous two analyses then a decision tree can
be plotted. The decision tree basically is a plot that contains
the various treatment options with the calculation of two fac-
tors (a) probability factor and (b) utility (or disutility) factor.
Figure 3 GRADE system.
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the probability of having an outcome with this treatment op-
tion. While utility/disutility factor expresses the value of the
outcome either by its costs/cost-effectiveness or by patient val-
ues and preferences for this outcome. From this tree a decision
can be made to adopt or decline certain type of intervention on
an individual patient case scenario (Guyatt and et al., 2008).
2.4. Stage of appropriateness analysis (ethical–legal and
societal)
The adoption of the technology frequently (if not always)
requires careful assessment not only the effectiveness of such
technology and its risk/beneﬁt balance, but also other ethical,
social and economic factors. It is logical that the effectiveness
of a particular technology constitutes the core component in
making a decision to adopt this technology. However, other
key factors should contribute to such decision such as the
appropriateness of this technology, its feasibility, its legality,
the patient access to it and its impact on the health system
and the society as a whole. This requires a complex type of
appropriateness analysis that may involve in some occasions
qualitative type of research. RAND Corporation developed
well structured methods for establishing appropriateness called
RAM (Rand Appropriateness method) that is widely used in
European countries (RAND). Ethical consideration arise in
HTA in the form of normative concepts (e.g., valuation of
human life); applications of technology (prevention, screening,
diagnosis, therapy, etc.); research and the advancement of
knowledge; allocation of resources. The equity in accessing
the medical technology also contributed in raising multiple
ethical questions regarding certain technologies.
As denoted in the literature (David Eddy, 2009) the meth-
odological progression of these stages is apparent. One cannot
estimate the magnitude of clinical outcomes (stage 2) withoutﬁrst evaluating the clinical evidence (stage 1). One cannot com-
pare the costs and cost-effectiveness (stages 3) without estimat-
ing the effects on the clinical outcomes (stage 2). One cannot
think about ethical and legal implications of the technology
(stage 4), until one knows something about the costs. These
stages are not only ordered methodologically, they are also
ordered in terms of their political and social acceptability. Un-
til very recently the appropriateness of a technology was deter-
mined pretty much by whatever physicians wanted to do. No
further information was needed. From the point of view of
physicians and patients, this is clearly a highly desirable
‘‘methodology’’ for determining the coverage of a technology.
It puts virtually no restrictions on what can be done or paid
for. Furthermore this method has prevailed for hundreds of
years. People are not only used to it, they are addicted to it.
The ﬁrst stage of a HTA, the analysis of evidence, is not only
younger (about 20-years old) but considerably more restrictive.
It says that before a physician can do something there must be
a systematic evaluation of evidence, and only those things that
are supported by good evidence will be paid for. The second
stage, which calls for estimating and comparing the magni-
tudes of beneﬁts and harms, is even more restrictive. It implies
that there is some threshold beyond which even effective treat-
ments might be denied if the beneﬁt risk ratio is considered too
small. Finally, an explicit consideration of costs is the most
restrictive of all. It explicitly states that effective technologies
can be denied if they are deemed to cost too much. In societies
where for decades few have had to pay directly for their health
care, this is the most obnoxious of all. So the fact that HTA
programs in different countries have progressed to different
stages reﬂects not only methodological concerns but social
and political concerns as well. The fact is that different coun-
tries have reached different stages in their social and political
acceptance of the different parts of an HTA. Correspondingly,
the HTA programs in different countries have reached
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are not ready for full HTAs and the difﬁcult choices (ration-
ing) they imply. Given the strengths of the methodologists
working around the world, it is almost certainly these social
and political constraints, and not the resource or methodolog-
ical constraints that have caused different programs to get
stuck at different phases in their HTAs (David Eddy, 2009).3. Deﬁnition of HTA
According to the International Network of Agencies for Health
Technology Assessment (INAHTA), HTA is a multidisciplin-
ary ﬁeld of policy analysis. It studies the medical, social, ethical,
and economic implications of development, diffusion, and use
of health technology (INAHTA). This deﬁnition implies a wide
array of research that goes beyond effectiveness. Health tech-
nology assessment is the systematic evaluation of properties, ef-
fects or other impacts of health technology. The main purpose
ofHTA is to inform policymaking for technology in health care,
where policymaking is used in the broad sense to include deci-
sions made at, e.g., the individual or patient level, the level of
the health care provider or institution, or at the regional, na-
tional and international levels. HTA may address the direct
and intended consequences of technologies as well as their indi-
rect and unintended consequences. HTA is conducted by inter-
disciplinary groups using explicit analytical frameworks,
drawing from a variety of methods.
HTA can be used in many ways to advise or inform tech-
nology-related policymaking. Among these are to advise or
inform:
 Regulatory agencies about whether to permit the commer-
cial use (e.g., marketing) of a drug, device or other
technology.
 Health care payers, providers, and employers about
whether technologies should be included in health beneﬁts
plans or disease management programs, addressing cover-
age (whether or not to pay) and reimbursement (how much
to pay).
 Clinicians and patients about the appropriate use of health
care interventions for a particular patient’s clinical needs
and circumstances.
 Health professional associations about the role of a technol-
ogy in clinical protocols or practice guidelines.
 Hospitals, health care networks, group purchasing organi-
zations, and other health care organizations about decisions
regarding technology acquisition and management.
 Standards-setting organizations for health technology and
health care delivery regarding the manufacture, use, quality
of care, and other aspects of health care technologies.
 Government health department ofﬁcials about undertaking
public health programs (e.g., vaccination, screening, and
environmental protection programs).
 Lawmakers and other political leaders about policies con-
cerning technological innovation, research and develop-
ment, regulation, payment and delivery of health care.
 Health care product companies about product development
and marketing decisions.
 Investors and companies concerning venture capital fund-
ing, acquisitions and divestitures, and other transactions
concerning health care product and service companies.Three basic orientations to HTA are as follows:
 Technology-oriented assessments are intended to determine
the characteristics or impacts of particular technologies.
For example, a government agency may want to determine
the clinical, economic, social, professional, or industrial
impacts of population-based CAD screening, or other par-
ticular interventions.
 Problem-oriented assessments focus on solutions or strate-
gies for managing a particular problem for which alterna-
tive or complementary technologies might be used. For
example, clinicians and providers concerned with the prob-
lem of diagnosis of CAD and DM may call for the develop-
ment of clinical practice guidelines involving some
combination or sequence of clinical history, clinical exami-
nation, and diagnostic imaging using various modalities.
 Project-oriented assessments focus on a local placement or
use of a technology in a particular institution, program,
or other designated project. For example, this may arise
when a hospital must decide whether or not to purchase a
magnetic resonance imaging (MRI) unit, considering the
facilities, personnel, and other resources needed to install
and operate an MRI unit; the hospital’s ﬁnancial status;
local market potential for MRI services; competitive fac-
tors; etc.
3.1. Value vs. cost
As an example, in HTA of the value of different strategies for
managing end-stage heart failure, Table 1 illustrates (Hogness
and Van Antwerp, 1991) that, although the cost of conven-
tional medical treatment is the lowest, its value per QALY is
the highest, as the life-years gained and the patient utility of
those years are low compared to the alternatives. The costs
of heart transplantation and total artiﬁcial heart are of similar
magnitude, but the value per QALY is much lower for heart
transplantation, as the life-years gained and the patient utility
of those years are higher compared to the total artiﬁcial heart.
3.2. HTA and underused technologies
When used properly, HTA can reduce or eliminate the use of
technologies that are not safe and effective, or whose cost is
too high relative to their beneﬁts. As discussed above, HTA
can also be used to remove technologies from the market that
are harmful or ineffective. On the other hand HTA can iden-
tify technologies that are underused, and to help determine
why they are underused. Some of the intervention that was
recognized to be underused in US despite its proven value
(McGlynn et al., 2003) is shown in Table 2.
3.3. Conﬂict of interest
HTA should consider the potential for conﬂict of interest on
multiple levels. One is on the part of investigators who con-
ducted and reported on the clinical trials and other studies that
comprise the body of evidence under review. A second is on the
part of sponsors of the primary research, e.g., technology
companies, who have varying degrees of control over what
research is conducted, selection of intervention and control
treatments, selection of endpoints and follow-up periods, and
Table 1 Cost and value for alternative therapies for end-stage heart disease (Hogness and Van Antwerp, 1991).
Therapy Life-years gained (year) Mean utility QALY (year) Aggregate cost ($) Cost per QALY ($/year)
Conventional medical treatment 0.50 0.06 0.03 $28,500 $950,000
Heart transplantation 11.30 0.75 8.45 $298,200 $35,290
Total artiﬁcial heart 4.42 0.65 2.88 $327,600 $113,750
Table 2 Underused health care technologies (US) (McGlynn
et al., 2003).
ACE inhibitors for treatment of heart failure
Beta blockers for survivors of acute myocardial infarction
Cholesterol-lowering drugs for patients at risk of coronary artery
disease
Implantable cardioverter-deﬁbrillators for survivors of cardiac
arrest
Smoking cessation interventions
Warfarin to prevent strokes due to atrial ﬁbrillation
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other is on the part of the health technology assessors them-
selves, including analysts, panel members, or other experts
involved in reviewing the evidence and making ﬁndings and
recommendations (Bekelman et al., 2003).
3.4. Horizon scanning
The demand for scanning of multiple types of sources for
information about new health care interventions has prompted
the development of ‘‘early warning’’ or ‘‘horizon scanning’’
functions in the US, Europe, and elsewhere (Douw et al.,
2003). Horizon scanning functions are intended to serve multi-
ple purposes, including to:
 Identify potential topics for HTA and information for set-
ting priorities among these.
 Clarify expectations for the uses or indications of a
technology.
 Increase public awareness about new technologies.
 Estimate the expected health and economic impacts.
 Identify critical thresholds of effectiveness improvements in
relation to additional costs, e.g., to demonstrate the cost-
effectiveness of a new intervention.
 Anticipate potential social, ethical, or legal implications of
a technology (Harper et al., 1998).
3.5. Moving from sporadic assessment to formal HTA
Even though a formal HTA programme might not be in place
in a given country, decision-making about the adoption of new
technologies may be part of the operational routine of health
authorities and health service providers (Deyo, 2002;
Hoffman, 2002). Decisions, however, are frequently based on
unilateral industry information, particular interests of individ-
uals or ‘‘gut feelings.’’ At best, decisions take into account
experience generated in other countries or selective expert ad-
vice. The challenge is to shift to a decision-making process that
follows modern principles such as Evidence-Based Medicine
(EBM), cost-effectiveness and patient centered services.Moving to a formalized and systematic HTA program requires
a solid commitment from governmental authorities and a des-
ignated and motivated team of professionals that take charge
of the HTA development plan. The establishment of one for-
mal ‘‘HTA Agency’’ should not necessarily be the sole focus
when targeting the creation or upgrading of national ‘‘HTA
capacity.’’ Quite often the establishment of a structured
HTA network integrating existing national institutions and
steered by an HTA commission (or HTA co-ordination board)
is a more appropriate solution (Lehoux et al., 2005).
4. Dissemination plan
NIH proposed few approaches for HTA report dissemination.
4.1. Target groups
 Clinicians (individuals and specialty/professional
organizations).
 Patients/consumers (individuals and organizations).
 Provider organizations (hospitals, clinics, and managed
care organizations)
 Third party payers (government and private sector).
 Quality assurance and utilization review organizations.
 Government policymakers (international, national, state,
and local).
 Biomedical researchers.
 Health care product companies.
 News professionals (popular and scientiﬁc/professional
journalists and editors).
 Educational institutions (schools and continuing profes-
sional education programs).4.2. Media
 Printed: direct mail, newspapers and popular journals, sci-
entiﬁc/professional journals and newsletters, posters,
pocket cards.
 Electronic: internet, television, radio, video disks, computer
databases (online and disk).
 Word of mouth: informal consultation, formal lectures and
presentations, focus groups.4.3. Implementation techniques or strategies
 Patient-oriented: mass media campaigns, community-based
campaigns, interaction with clinicians (including shared
decision procedures and interactive video disk), modify
insurance coverage (more or less generous beneﬁts and
change copayments).
 Clinician-oriented: conferences and workshops; continuing
professional education; professional curriculum develop-
ment; opinion leaders; one-on-one educational visits
(‘‘academic detailing’’); coverage/reimbursement policy;
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restrictions; feedback (e.g., on laboratory test ordering rel-
ative to criteria/guidelines); reminder systems (e.g., as part
of computer-based patient record systems); medical audit/
peer review; criteria for board certiﬁcation/recertiﬁcation,
state licensure, Medicare PRO action, specialty designation,
professional/specialty society membership; public availabil-
ity of performance data (e.g., adjusted mortality rates for
certain procedures); defense against sanctions and malprac-
tice action.
 Institution-oriented: accreditation, standards (e.g., hospital
infection control and clinical laboratories), benchmarking,
public availability of performance data.
5. Decentralization of HTA
Although technology assessment originated as a primarily cen-
tralized function conducted by federal government agencies or
other national- or regional-level organizations, HTA has be-
come a more decentralized activity conducted by a great vari-
ety of organizations in the public and private sectors that make
technology-related policy decisions. As noted above, an HTA
done from a particular perspective may not serve the technol-
ogy-related policymaking needs of other perspectives. Even for
the same technology or clinical problem, there can be widely
different assessment needs of politicians, regulatory agencies,
health technology companies, hospitals, payers, physicians,
and others. These needs are heightened with increased
economic responsibilities and pressures on these different
parties.
Increasingly, large health care providers and major health
care product companies are establishing units devoted to
‘‘technology assessment,’’ ‘‘pharmacoeconomics,’’ ‘‘clinical
effectiveness,’’ ‘‘health outcomes research,’’ and related areas.
More health plans (including various managed care organiza-
tions and insurance companies) have established formal pro-
grams to assess new procedures and other technologies in
support of payment decisions. The number and magnitude of
private ﬁrms and university centers involved in HTA is increas-
ing. HTA committees (with various names) are now common
among medical specialty and subspecialty societies. Hospital
networks, managed care organizations and other large health
care providers in the private sector have HTA programs to
support acquisition and management of pharmaceuticals
(e.g., P&T committees), equipment and other technologies
and other technology-related needs throughout their systems
(Kaden et al., 2002).
The nature of an assessment problem will affect the deter-
mination of the most appropriate organization to conduct it.
Certainly, a comprehensive HTA addressing multiple attri-
butes of a technology can be very resource intensive, requiring
considerable and diverse expertise, data sources, and other re-
sources. Some health care organizations, such as some minis-
tries of health and national health services, major insurance
companies, health plans, and integrated health systems, have
their own internal HTA programs. For example, in a large
hospital or health plan, this might include a core staff and a
multidisciplinary HTA committee representing major clinical
departments, nursing, pharmacy, allied health, biomedical
engineering. This committee might interact with other commit-
tees such as pharmacy and therapeutics (‘‘P&T’’), strategicplanning, and capital planning committees. Other organiza-
tions rely on assessment reports acquired from organizations
that have devoted functions or otherwise specialize in HTA.
Health care decision makers can ‘‘make or buy’’ HTAs.
Determining the responsibility for sponsoring or conducting
an assessment depends upon the nature of the problem, ﬁnan-
cial resources available, expertise of available personnel, time
constraints, and other factors. For any assessment problem,
an organization must determine the extent to which it will
devote its resources to conducting the assessment itself or
purchasing it from other sources. Some health care organiza-
tions commission selected components of an HTA, such as
evidence retrieval and synthesis, and perform the other steps
in-house.
One of the potential advantages of requesting or commis-
sioning an outside group to conduct HTAs is to gain an inde-
pendent, outside view where a requesting agency might have a
perceived conﬂict of interest. Thus, a major health care payer
might seek an HTA from an outside group to inform its
coverage decision about a costly new technology in order to
diminish perceptions of a potential bias against making a deci-
sion not to cover the technology (NIH).6. Barriers to HTA
Although the general trend in health care is toward wider and
improved HTA, several countervailing forces to HTA remain.
Foremost, particularly in the US and other wealthy countries,
has been a ‘‘technological imperative’’ comprising an abiding
fascination with technology, the expectation that new is better,
and the inclination to use a technology that has potential for
some beneﬁt, however marginal or even poorly substantiated
(Deyo, 2002). Some argue that the increased potential of tech-
nology only raises the imperative for HTA (Hoffman, 2002).
Another countervailing factor is the sway of prestigious propo-
nents or a ‘‘champion’’ of a technology in the absence of cred-
ible evidence. A third impediment is the inertia of medical
practice, e.g., in the form of reluctance to change long-standing
practice routines, conservative payment policies, and quickly
outdated education. This is complemented by lack of opportu-
nities for, or encouragement of, scientiﬁc inquiry and skepti-
cism in clinical education.
Ever more effective marketing and promotions, including
short courses sponsored by medical product companies to
train physicians in using these products, can divert attention
from key concerns of HTA. Another obstacle is the limited
level of investment, by government and industry sources in
HTA and related evaluations of what works in health care.
Although some assessment programs and certain HTA ﬁnd-
ings are nationally or internationally recognized, the re-
sources allocated for HTA in the US are virtually lost in
the rounding error of national health care expenditures. Fi-
nally, the impression persists in some quarters that the goal
of HTA is to limit the innovation and diffusion of health care
technology (NIH).7. Chain of EBM–HTA
In summary, every HTA begins with an evaluation of the evi-
dence for the technology being assessed. In that sense EBM
and HTA constitute a continuum. EBM itself has two parts
Figure 4 (A) EBM and HTA. (B) EBM and HTA.
Health technology assessment (HTA) in cardiac ﬁeld 83(Eddy, 2005). One is evidence-based individual decision-mak-
ing (EBID). As the name implies this type of EBM focuses
on the evidence pertaining to an individual patient’s manage-
ment. As originally proposed, it emphasizes the education of
physicians in how to bring evidence to bear on decisions about
individual patients (Evidence-Based Medicine Working
Group, 1992), and the synthesis of evidence with clinical judg-
ment (Sackett et al., 1996). The other part is evidence-based
guidelines (EBGs) and clinical recommendations (CR). This
part describes the importance of basing population-based pol-
icies like recommendations, guidelines, policies, decisions, and
performance measurement on evidence and it is this part that
stresses the principle that before any population-based policy
can be promoted there should be good evidence about favor-
able effectiveness and beneﬁt/harm ratio. The next wider scope
of this population based or more generally evidence-based
practice policymaking will involve more economical and soci-
etal factors that inﬂuence the whole health system. Thus thecontinuum of EBM and HTA can be illustrated in Fig. 4A
and B which you may call ‘‘EBM–HTA chain.’’
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